Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1)

Journal of Medicinal Chemistry

Volumn 54, Issue 24, 2011, Pages 8490-8500

  Murphy, Sean T ^a,b   Alton, Gordon ^a   Bailey, Simon ^a   Baxi, Sangita M ^a   Burke, Benjamin J ^a   Chappie, Thomas A ^a   Ermolieff, Jacques ^a   Ferre, RoseAnn ^a   Greasley, Samantha ^a   Hickey, Michael ^a   Humphrey, John ^a   Kablaoui, Natasha ^a   Kath, John ^a   Kazmirski, Steven ^a   Kraus, Michelle ^a   Kupchinsky, Stan ^a   Li, John ^a   Lingardo, Laura ^a   Marx, Matthew A ^a   Richter, Dan ^a   Tanis, Steven P ^a   Tran, Khanh ^a   Vernier, William ^a   Xie, Zhi ^a   Yin, Min Jean ^a   Yu, Xiao Hong ^a   more..

^a PFIZER INC   (United States)

^b Takeda San Diego Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(4 AMINO 7 ISOPROPYL 7H PYRROLO[2,3 D]PYRIMIDIN 5 YL)PYRAZIN 2 YLMETHANONE; 1 [3 [6 (4 AMINO 7 ISOPROPYL 7H PYRROLO[2,3 D]PYRIMIDINE 5 CARBONYL)PYRAZIN 2 YLAMINO] 2 (4 FLUOROPHENYL) PYRROLIDIN 1 YL]ETHANONE; 1 [3 [6 (4 AMINO 7 ISOPROPYL 7H PYRROLO[2,3 D]PYRIMIDINE 5 CARBONYL)PYRAZIN 2 YLAMINO] 2 PHENYLPYRROLIDIN 1 YL]ETHANONE; 3 [6 (4 AMINO 7 ISOPROPYL 7H PYRROLO[2,3 D]PYRIMIDINE 5 CARBONYL)PYRAZIN 2 YLAMINO] 2 (4 FLUOROPHENYL) PYRROLIDINE 1 CARBALDEHYDE; ANTINEOPLASTIC AGENT; FLUORINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 INHIBITOR; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRAZINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATION ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; IN VITRO STUDY; LIPOPHILICITY; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; ETHYLAMINES; HUMANS; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; PYRROLES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84055217593     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201019k     Document Type: Article

References (31)

1. Kobayashi, T.; Cohen, P. Activation of serum- and glucocorticoid- regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem. J. 1999, 339, 319-328.
2. Mora, A.; Komander, D.; van Aalten, D. M.; Alessi, D. R. PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 2004, Apr 15, 161-170.
3. Raimondi, C.; Falasca, M. Targeting PDK1 in Cancer. Curr. Med. Chem. 2011, 18, 2763-2769.
4. Bayascas, J. R.; Leslie, N. R.; Parsons, R.; Fleming, S.; Alessi, D. R. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(±) mice. Curr. Biol. 2005, 15, 1839-1846.
5. Zeng, X.; Xu, H.; Glazer, R. I. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. Cancer Res. 2002, 62, 3538-3543.
6. Li, Y.; Yang, K. J.; Park, J. Multiple implications of 3-phosphoinositide-dependent protein kinase 1 in human cancer. World J. Biol. Chem. 2010, 1, 239-247.
7. Peifer, C.; Alessi, D. R. Small-molecule inhibitors of PDK1. ChemMedChem 2008, 3, 1810-1838.
8. Angiolini, M.; Banfi, P.; Casale, E.; Casuscelli, F.; Fiorelli, C.; Saccardo, M. B.; Silvagni, M.; Zuccotto, F. Structure-based optimization of potent PDK1 inhibitors. Bioorg. Med. Chem. Lett. 2010, 20, 4095-4099.
9. Najafov, A.; Sommer, E. M.; Axten, J. M.; Deyoung, M. P.; Alessi, D. R. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem. J. 2010, 433, 357-369.
10. Nagashima, K.; Shumway, S. D.; Sathyanarayanan, S.; Chen, A. H.; Dolinski, B.; Xu, Y.; Keilhack, H.; Nguyen, T.; Wiznerowicz, M.; Li, L.; Lutterbach, B. A.; Chi, A.; Paweletz, C.; Allison, T.; Yan, Y.; Munshi, S. K.; Klippel, A.; Kraus, M.; Bobkova, E. V.; Deshmukh, S.; Xu, Z.; Mueller, U.; Szewczak, A. A.; Pan, B. S.; Richon, V.; Pollock, R.; Blume-Jensen, P.; Northrup, A.; Andersen, J. N. Genetic and pharmacological inhibition of PDK1 in cancer cells: Characterization of a selective allosteric kinase inhibitor. J. Biol. Chem. 2011, 286, 6433-6448.
11. (a) Islam, I.; Bryant, J.; Chou, Y. L.; Kochanny, M. J.; Lee, W.; Phillips, G. B.; Yu, H.; Adler, M.; Whitlow, M.; Ho, E.; Lentz, D.; Polokoff, M. A.; Subramanyam, B.; Wu, J. M.; Zhu, D.; Feldman, R. I.; Arnaiz, D. O. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: Design, synthesis and biological activity. Bioorg. Med. Chem. Lett. 2007, 17, 3814-3818.
12. (b) Islam, I.; Brown, G.; Bryant, J.; Hrvatin, P.; Kochanny, M. J.; Phillips, G. B.; Yuan, S.; Adler, M.; Whitlow, M.; Lentz, D.; Polokoff, M. A.; Wu, J.; Shen, J.; Walters, J.; Ho, E.; Subramanyam, B.; Zhu, D.; Feldman, R. I.; Arnaiz, D. O. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517. Bioorg. Med. Chem. Lett. 2007, 17, 3819-3825.
13. Gopalsamy, A.; Shi, M.; Boschelli, D. H.; Williamson, R.; Olland, A.; Hu, Y.; Krishnamurthy, G.; Han, X.; Arndt, K.; Guo, B. Discovery of dibenzo[c,f][2,7]naphthyridines as potent and selective 3-phosphoinositide- dependent kinase-1 inhibitors. J. Med. Chem. 2007, 50, 5547-5549.
14. Stauffer, F.; Maira, S. M.; Furet, P.; García-Echeverría, C. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg. Med. Chem. Lett. 2008, 18, 1027-1030.
15. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127-132.
16. Lind, K. E.; Lin, E. Y.; Nguyen, T. B.; Tangonan, B. T.; Cao, K.; Erlanson, D. A.; Guckian, K.; Simmons, R. L.; Lee, W.; Sun, L.; Hansen, S.; Pathan, N.; Zhang, L. Pyridinonyl PDK1 inhibitors. PCT Int. Appl. 2008, WO2008/5457 A2.
17. Shepherd, T. A.; Aikins, J. A.; Bleakman, D.; Cantrell, B. E.; Rearick, J. P.; Simon, R. L.; Smith, E. C. R.; Stephenson, G. A.; Zimmerman, D. M.; Mandelzys, A.; Jarvie, K. R.; Ho, K.; Deverill, M.; Kamboj, R. K. Design and synthesis of a novel series of 1,2-disubstituted cyclopentanes as small, potent potentiators of 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA) receptors. J. Med. Chem. 2002, 45, 2101-2111.
18. Andreotti, D.; Ward, S. E. Preparation of N-[2-phenyl-tetrahydrofuran-3- yl]-2-propanesulfonamide derivatives as glutamate receptor modulators. PCT Int. Appl. 2007, WO2007090841.
19. Xu, Z.; Lu, X. Phosphine-catalyzed [3 + 2] cycloaddition reactions of substituted 2-alkynoates or 2,3-allenoates with electron-deficient olefins and imines. Tetrahedron Lett. 1999, 40 (3), 549-552.
20. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: A useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431.
21. Michel, J.; Tirado-Rives, J.; Jorgensen, W. L. Energetics of displacing water molecules from protein binding sites: Consequences for ligand optimization. J. Am. Chem. Soc. 2009, 131, 15403-15411.
22. Zlokarnik, G.; Grootenhuis, P. D. J.; Watson, J. B. High throughput P450 inhibition screens in early drug discovery. Drug Discovery Today 2005, 10, 1443-1450.
23. Andrews, P. R.; Craik, D. J.; Martin, J. L. Functional group contributions to drug-receptor interactions. J. Med. Chem. 1984, 27, 1648-1657.
24. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 2008, 51, 817-834.
25. Analiza Inc., 3615 Superior Avenue, Suite 4407B, Cleveland, OH 44114. Solubility assay: http://www.analiza.com/adme/aqueous-solubility.html.
26. Researchers at Johnson and Johnson (Reynolds, C. H.; Tounge, B. A.; Bembenek, S. D. Ligand binding efficiency: Trends, physical basis, and implications. J. Med. Chem. 2008, 51, 2432-2438.
27. Liu, K.; Zhu, J.; Smith, G. L.; Yin, M.; Bailey, S.; Chen, J. H.; Hu, Q.; Huang, Q.; Li, C.; Li, Q. J.; Marx, M. A.; Paderes, G.; Richardson, P. F.; Sach, N. W.; Walls, M.; Wells, P. A.; Zou, A. Highly selective and potent thiophenes as PI3K inhibitors with oral antitumor activity. Med. Chem. Lett. 2011, 2, 809-813.
28. Johnson, T. W.; Bailey, S.; Baxi, S. M.; Brooun, A.; Dinh, D. M.; He, M.; Hoffman, J. E.; Kan, J. L. C.; Lam, H.; Li, C.; Mehta, P. P.; Sach, N. W.; Smeal, T.; Walls, M.; Wells, P.; Yin, M.; Yu, X.; Zou, A. The chemistry and biology of mTOR selective inhibitors. AACR Special Conference: Targeting PI3K/mTOR Signaling in Cancer, Feb. 24-27, 2011, San Francisco, CA.
29. Hofler, A.; Nichols, T.; Grant, S.; Lingardo, L.; Esposito, E. A.; Gridley, S.; Murphy, S. T.; Kath, J. C.; Cronin, C. N.; Kraus, M.; Alton, G.; Xie, Z.; Sutton, S.; Gehring, M.; Ermolieff, J. Study of the PDK1/ AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays. Anal. Biochem. 2011, 414, 179-186.
30. GraphPad Prism, version 5.01; GraphPad Software Inc.: San Diego.
31. Morrison, J. F. Kinetics of the reversible inhibition of enzyme catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 1969, 185, 269-286.